Sukhvinder Singh Sukhu, the Chief Minister of Himachal Pradesh, has taken a significant step towards improving healthcare in the state by directing officials to prepare a new 'Essential Drugs' list. This initiative aims to enhance the availability of quality medicines in government health institutions, ensuring that patients receive the best possible care. During a review meeting held on February 4, Sukhu emphasized the importance of this list being evaluated by a high-powered committee to ensure its effectiveness.
The chief minister articulated that the move towards direct procurement from manufacturers is not merely a cost-cutting measure; rather, it is a strategic decision aimed at eliminating delays caused by middlemen in the supply chain. By bypassing intermediaries, the state government intends to secure a consistent inventory of life-saving drugs, which is crucial for patient care. This approach will allow for better management of resources and a more transparent procurement process.
- Direct procurement from manufacturers — aims to eliminate middleman delays.
- Strengthened quality testing — dedicated cells in medical colleges for better oversight.
- Strict enforcement of regulations — ensures compliance with the Drugs and Cosmetics Rules.
In addition to the new drug list, Sukhu highlighted the need for strengthening the mechanism for sampling and quality testing of medicines supplied to government health institutions. He proposed the establishment of dedicated cells in each medical college across the state, with adequate staffing, training, and necessary equipment. The first phase of this initiative will see the cells set up at IGMC-Shimla and Dr RPGMC-Tanda, which will be pivotal in ensuring that the quality of medicines meets the required standards.
Furthermore, the chief minister instructed officials to enforce strict quality checks on medicines manufactured by pharmaceutical companies within the state. He reiterated that no compromises would be made regarding patients' health and that adherence to the provisions of Schedule-M of the Drugs and Cosmetics Rules, 1945, is paramount. This commitment to quality and transparency in the healthcare sector is expected to significantly enhance the trust of the public in government health services.
